1-2

Aristo started its operations in 1971 with a manufacturing plant at Aurangabad, marketing operations in Mumbai with a field force of just 30 personnel. Since then Aristo has come a long way... From a turnover of US $ 8500 in 1971 to US $ 64 million in year 2000.

Troikaa mainly focuses on Novel Drug Delivery Systems (NDDS). The company firmly believes in providing superior therapeutic benefits by improvising the formulations through Innovative Technologies.
Six patents have been filed in various areas of drug delivery. To handle competition, Troikaa adopted various multifaceted strategies to help stand their ground in the competitive market. Another fact that helps us stand out is their high quality products.

Headquartered in Mumbai India, GenPharma is with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment.
Everyday, they strive to discover new medicines that are designed to improve the health and quality of life of patients around the world - medicines which are innovative, effective and which offer added benefits such as reduced side effects or better ways of functioning.

Alembic Limited, with an established presence in the Indian pharma  industry has a proud, historical track record going back one hundred years. With a turnover in excess of Rs1000 crores today, Alembic Limited is one of India’s leading integrated pharmaceutical companies.

Ajanta Pharma Limited is an emerging, global pharmaceutical company with proven capabilities in the areas of product research, manufacturing & marketing.

Their vision is to become a leading pharmaceutical company by providing cost effective and high quality treatment and preventive medication to improve the quality of Life. Their company focusses on ensuring Quality and creating value for patients, employees and stakeholders.

Sree Chitra Tirunal Institute for Medical Sciences & Technology (SCTIMST), Thiruvananthapuram is an Institute of National Importance  established by an Act  of the Indian Parliament  and  under the 2 administrative control of the Department of Science and Technology, Government of India.

Glenmark Pharmaceuticals today announced the settlement of litigation with Daiichi Sankyo and Genzyme Corporation regarding Glenmark's Abbreviated New Drug Application (ANDA) tiled with the US Food and Drug Administration (FDA) for Colesevelam Hydrochloride, a drug used in treatment of type-2 diabetes.